Business
Abattis annouces Phytalab CSO presents at 24th annual ICRS meeting in Italy
Abattis annouces Phytalab CSO presents at 24th annual ICRS meeting in Italy.
About this update from Abattis Bioceuticals Corp
[{"type":"text","content":"\n\nv\\:* {behavior:url(#default#VML);}\no\\:* {behavior:url(#default#VML);}\nw\\:* {behavior:url(#default#VML);}\n.shape {behavior:url(#default#VML);}\n\n\n\nABATTIS\nANNOUNCES PHYTALAB CSO PRESENTS AT\n\n24TH\nANNUAL ICRS MEETING IN ITALY\n\n \n\n \n\nVancouver, BC ? Wednesday\nJune 10, 2014 - Abattis Bioceuticals Corp. (the ?Company? or ?Abattis?) (OTC\nPINK: ATTBF) (CSE: ATT), through its wholly owned Washington subsidiary Abattis\nBioceuticals International Inc. is pleased to\nannounce Dr. Sexton, CSO of Phytalab LLC in Kirkland, WA, will\nhave an oral presentation at the upcoming 24th Annual International\nCannabinoid Research Society (ICRS) meeting in Baveno Italy. Dr. Sexton has\nbeen a member of the ICRS since 2007 and has previously presented for the\nICRS. She served on the program\ncommittee for this 2014 symposium on Cannabinoids. Her talk is entitled ?A\nMEDICAL ETHNOGRAPHIC REPORT OF CANNABIS USE IN PEDIATRIC INTRACTABLE\nEPILEPSY (IE) PATIENTS? and\nwill be presented during a session on ?CNS and Psychiatric\nIssues?, June 30th. Dr.\nSexton will also be chairing a session with Luciano di Petrocellis entitled ?\nBeyond THC: Cannabidiol and Other\nComponents.? The five-day conference is\nthe meeting for a group of over 500\nactive researchers in all fields of the cannabinoids and related bioactive\nlipids. Dr. Sexton commented ?I am honored that ICRS President Ethan Russo gave\nme the opportunity to participate in this historic organization, and proud to\nhave earned the opportunity to discuss research with a fabulous collection of\nthinkers?. \n\nThe\ncompany is also pleased to announce PhytaLab is in the process of submission\nthe extensive paperwork and data collection necessary for receiving provisional\nstatus for testing of Cannabis and related products under I502 in Washington\nState. Application for the certification\nby the State enables Phytalab to expand testing for the medical Cannabis market\nto testing in the new marketplace.\n\nMike\nWithrow, CEO of Abattis stated \"We are proud of the work Dr. Sexton and\nthe team at Phytalab.com are doing. The team is on target and meeting all of\ntheir milestones.\"\n\n \n\n \n\nAbout Abattis Bioceuticals Corp.\n\n \n\nAbattis is a specialty biotechnology company with\ncapabilities through its ...